Cambridge Investment Research Advisors, Inc. Invitae Corp Transaction History

Cambridge Investment Research Advisors, Inc.

$26 Billion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.42 - $0.72 $17,291 - $29,643	-41,171 Reduced 40.9%	59,489 $37,000
Q3 2023 Oct 24, 2023	SELL	$0.6 - $1.53 $28 - $73	-48 Reduced 0.05%	100,660 $61,000
Q2 2023 Jul 13, 2023	BUY	$1.05 - $1.63 $33,903 - $52,631	32,289 Added 47.19%	100,708 $114,000
Q1 2023 May 11, 2023	BUY	$1.2 - $2.73 $198 - $450	165 Added 0.24%	68,419 $92,000
Q4 2022 Feb 08, 2023	SELL	$1.71 - $3.61 $441 - $931	-258 Reduced 0.38%	68,254 $127,000

Q3 2022 Oct 17, 2022	BUY	$1.9 - $8.63 $6,425 - $29,186	3,382 Added 5.19%	68,512 $168,000
Q2 2022 Jul 13, 2022	BUY	$2.13 - $9.01 $17,610 - $74,494	8,268 Added 14.54%	65,130 $158,000
Q1 2022 May 12, 2022	BUY	$6.28 - $15.59 $111,815 - $277,579	17,805 Added 45.59%	56,862 $453,000
Q4 2021 Feb 03, 2022	SELL	$14.7 - $28.67 $19,962 - $38,933	-1,358 Reduced 3.36%	39,057 $596,000
Q3 2021 Nov 02, 2021	BUY	$24.31 - $33.6 $97,653 - $134,971	4,017 Added 11.04%	40,415 $1.15 Million
Q2 2021 Aug 10, 2021	BUY	$26.09 - $40.4 $40,804 - $63,185	1,564 Added 4.49%	36,398 $1.23 Million
Q1 2021 May 07, 2021	BUY	$33.06 - $56.93 $668,737 - $1.15 Million	20,228 Added 138.49%	34,834 $1.33 Million
Q4 2020 Feb 04, 2021	SELL	$39.09 - $57.4 $82,128 - $120,597	-2,101 Reduced 12.58%	14,606 $610,000
Q3 2020 Oct 29, 2020	BUY	$28.43 - $44.67 $94,302 - $148,170	3,317 Added 24.77%	16,707 $724,000
Q2 2020 Jul 27, 2020	SELL	$11.71 - $30.29 $117 - $302	-10 Reduced 0.07%	13,390 $405,000
Q1 2020 May 08, 2020	BUY	$7.64 - $27.5 $102,376 - $368,500	13,400 New	13,400 $183,000

Others Institutions Holding NVTA

# of Institutions

Shares Held

7.66M

Call Options Held

Put Options Held

View Full List

About Invitae Corp

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

More about NVTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account